Ambulatory surgery center company AmSurg received a neutral rating from Zacks in a Monday report, according to a WKRB News & Analysis report.
Here are five key updates on AmSurg stock:
1. The current price target is $58.
2. Stock traded down 0.83 percent mid-day Monday, Dec. 29, hitting $54.75.
3. The company's 52-week low is $40 and high is $55.61.
4. AmSurg has a market cap of $2.59 billion.
5. The company closed at $55.10 on Monday and opened at $54.89 on Tuesday, Dec. 30.
Third quarter revenue was up 91.3 percent from the same period in 2013, but still failed to meet estimates. Analysts predict AmSurg will post $2.64 earnings per share for the current fiscal year.
"Apart from strong performance of Sheridan, improved average revenues per procedure and increased same-center revenues were encouraging," said a Zacks analyst, quoted in the report. "The Sheridan acquisition has paved AmSurg's way into the huge and fast-growing fragmented physician outsourcing market. Nonetheless, headwinds like reduction in workers' compensation reimbursement, sequestration and increased interest expense are intimidating."
As a result, Zacks gave AmSurg a neutral rating.